About
Stipple Bio is a biotechnology company harnessing epitope-level precision to create targeted cancer therapies through our proprietary Pointillist Platform, which is designed to identify tumor-specific cell surface epitopes with greater precision. By enabling more selective targeting of cancer cells, the platform aims to improve therapeutic index and unlock targets that have been difficult to address using conventional oncology drug discovery methods. We’re advancing our lead candidate ADC STP-100 as an early application of our epitope-targeting approach. Founded in 2022 by cancer biology pioneers Aaron Ring (Fred Hutchinson Cancer Center) and Aashish Manglik (University of California, San Francisco), Stipple Bio is grounded in deep expertise across cancer biology, chemical biology and translational science. Our financing was co-led by RA Capital, a16z Bio+Health and Nextech Invest, and includes participation from existing investors Emerson Collective Investments (managed by Yosemite), GV (Google Ventures), LoLa Capital Partners and GordonMD Global Investments, among others. Stipple Bio is building a pipeline of next-generation oncology therapeutics with the goal of developing life-changing medicines for cancer patients.
Product
- Value proposition
- Revolutionizing targeted oncology with epitope-level precision to develop life-changing medicines for people with cancer.
- Target customers
- biotech and pharmaceutical companies
Founders
- Aaron Ring
- Aashish Manglik
Categories
Products
Key features
Technologies
Integrations
Target conditions
Investors
News
- Stipple Bio Emerges From Stealth with Oversubscribed $100 Million Series A Financing to Advance STP-100 into Early Clinical Studies and Advance a Precision Oncology Pipeline that Leverages its Pointillist Platform - BioSpace · 2026-04-06T13:11:48.000Z
- Stipple Bio launches with $100M to find more precise targets on cancer proteins · 2026-04-06T11:00:13.000Z
- BioCentury - Stipple: Epitope-level precision for safer cancer therapies · 2026-04-10T20:35:15.000Z
- Stipple Bio step onto the scene with $100m Series A · 2026-04-10T09:09:19.000Z
- Investing in Stipple Bio | Andreessen Horowitz · 2026-04-06T11:57:46.000Z
- Stipple Bio Emerges From Stealth with Oversubscribed $100 Million Series A Financing to Advance STP-100 into Early Clinical Studies and Advance a Precision Oncology Pipeline that Leverages its Pointillist Platform · 2026-04-06T11:00:00.000Z
More links
Browse similar startups
Related startups
- The Part-Time Benefits Company — Billerica, MA
- Torus Biosystems — Medford, MA
- UterineKind — Boston, MA
- Venova Technologies — Cambridge, MA
- Vitalic Health — Boston, MA
- Xeomics — Boston, MA
- Symbiome — San Francisco, CA
- Synamics Therapeutics — Beverly Hills, CA
- TwoStep Therapeutics — San Carlos, CA
- Acrobat Genomics — San Carlos, CA
- AivoCode — San Diego, CA
- Arialys Therapeutics — La Jolla, CA
Profile updated Jul 29, 2026. Sources: stipple.bio, linkedin.com
